Tuesday April 01, 2025
07:00-08:00
ON-DEMAND SYMPOSIA - ONLINE ONLY
On-Demand Oral Gallery
08:00-15:30
PRE-CONFERENCE SYMPOSIUM 01
Hall F1
PRE-CONFERENCE SYMPOSIUM 01
Hall F2
08:45-10:45
AD MECHANISMS AND MOLECULAR SYSTEMS
Hall B
10:45-12:45
WHITE MATTER ALTERATIONS AND MRI
Hall A
ALPHA-SYNUCLEINOPATHIES: DISEASE MECHANISMS, PATHOPHYSIOLOGY
Hall E
AD & PD: INSIGHTS FROM GENETICS 01
Hall B
11:00-15:30
PRE-CONFERENCE SYMPOSIUM 02
Hall C
12:45-13:15
BREAK
Exhibition
13:15-15:30
BIOMARKERS, IMAGING. AND TRANSLATIONAL ASPECTS
Hall A
ADVANCES IN PD TREATMENT
Hall E
13:15-15:15
SYMPTOM DETECTION AND TREATMENT PROGRAMS: HEALTH CORRELATES AND APPS
Hall B
15:45-16:35
OPENING CEREMONY AND AWARDS
Hall A
16:35-17:05
PLENARY LECTURE 01
Hall A
17:05-17:35
PLENARY LECTURE 02
Hall A
17:35-17:45
SHORT BREAK
Exhibition
17:45-18:45
FORUM 01: VARYING REGULATORY PHILOSOPHIES AND AD APPROVAL PRIORITIES - USA, EU, ASIA, AND OTHER PARTS OF THE WORLD
Hall A
18:45-19:30
FIRESIDE CHAT 03
Hall A
19:35-21:25
WELCOME RECEPTION IN EXHIBITION
Exhibition
Wednesday April 02, 2025
07:00-08:00
ON-DEMAND SYMPOSIA - ONLINE ONLY
On-Demand Oral Gallery
08:00-08:30
PLENARY LECTURE 03: Don Price Memorial Lecture
Hall A
08:30-08:40
BREAK
Exhibition
08:40-10:40
INDUSTRY SYMPOSIUM 01 (NO CME/CPD CREDIT)
Hall A
DEMENTIA PREVENTION AND TREATMENT STRATEGIES; DIAGNOSIS AND STAGING OF AD
Hall E
APOE MECHANISMS AND TREATMENT STRATEGIES
Hall B
ABETA TOXICITY: OLIGOMERS, PLAQUES AND INTERACTION WITH TAU
Hall C
EXTRACELLULAR VESICLES AND BRAIN PATHOLOGY
Hall F1
GENETIC AND EPIDEMIOLOGICAL INSIGHTS IN AD & PD
Hall F2
10:40-11:10
PRODUCT THEATER 01 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
Exhibition/Product Theater
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
11:10-12:50
INDUSTRY SYMPOSIUM 02 (NO CME/CPD CREDIT)
Hall A
12:50-13:50
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
Exhibition
13:00-13:30
PRODUCT THEATER 02 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
Exhibition/Product Theater
13:50-14:50
FORUM 02: INTEGRATING BLOOD-BASED, CSF AND IMAGING BIOMARKERS WITH DIGITAL TOOLS AND AI IN MCI & AD: HOW CLOSE ARE WE TO VALIDATION IN STANDARD OR PRECISION MEDICINE?
Hall A
13:50-15:50
TREM2, MICROGLIA: FROM MECHANISMS TO POTENTIAL TREATMENTS
Hall E
GENETICS OF NEURODEGENERATION: NEW FINDINGS AND ASSOCIATIONS
Hall B
ALPHA--SYNUCLEIN, AGGREGATION, MISFOLDING, PATHOGENESIS AND TRANSLATIONAL ASPECTS
Hall C
TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 01
Hall F1
WHITE MATTER ALTERATIONS
Hall F2
14:50-15:50
FORUM 03: IMPROVING THE THERAPEUTIC POTENTIAL OF IMMUNOTHERAPIES IN AD – CAN NOVEL STRATEGIES OR NEXT GENERATION DRUGS HALT OR FURTHER DELAY DISEASE PROGRESSION?
Hall A
15:50-16:20
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
16:20-18:20
INDUSTRY SYMPOSIUM 03 (NO CME/CPD CREDIT)
Hall A
16:20-18:50
TAU MECHANISMS 01
Hall E
ANCESTRY AND GENETICS OF NEURODEGENERATION
Hall B
PD & LBD: ADVANCES IN DIAGNOSIS
Hall C
TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 02
Hall F1
MITOCHONDRIA AND NEURODEGENERATION, GLUCOCORTICOID VULNERABILITY
Hall F2
18:25-19:25
NEURODEGENERATIVE DISEASES: DIAGNOSIS & STAGING
Hall A
Thursday April 03, 2025
07:00-08:00
ON-DEMAND SYMPOSIA - ONLINE ONLY
On-Demand Oral Gallery
08:00-08:30
PLENARY LECTURE 04: The Eric N. Birch Memorial Lecture
Hall A
08:40-10:40
INDUSTRY SYMPOSIUM 04 (NO CME/CPD CREDIT)
Hall A
CHOLINERGIC MECHANISMS IN AD AND PD (1)
Hall E
APOE: DISEASE MECHANISMS AND BIOLOGY
Hall B
AUTOPHAGY
Hall C
DISEASE AND RESILIENCE MECHANISMS: INFLAMMATION, ASTROGLIA, AND MORE
Hall F1
SEX SIMILARITIES AND DIFFERENCES IN BIOMARKERS & PATHOPHYSIOLOGY
Hall F2
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
11:10-12:50
INDUSTRY SYMPOSIUM 05 (NO CME/CPD CREDIT)
Hall A
12:50-13:50
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
Exhibition
13:50-15:50
INDUSTRY SYMPOSIUM 06 (NO CME/CPD CREDIT)
Hall A
ABETA TARGETING THERAPIES IN AD 01
Hall E
LIPIDS IN AD & PD
Hall B
MECHANISMS (TDP-43, C9ORF72, TMEM106B) AND CLINICAL TRIALS IN FTD, ALS AND NEURODEGENERATION 01
Hall C
FLUID BIOMARKERS AND MULTIMODAL IMAGING FOR DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION
Hall F1
Α-SYNUCLEIN AGGREGATION. PROPAGATION AND NEUROTOXICITY
Hall F2
15:50-16:20
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
16:20-17:20
INDUSTRY SYMPOSIUM 07 (NO CME/CPD CREDIT)
Hall A
16:20-18:20
ARIA, MICROBLEEDS, CAA
Hall E
TAU MECHANISMS 02 & PSP
Hall B
PET AND MULTIMODAL IMAGING
Hall C
FLUID BIOMARKERS. AND IMAGING 01
Hall F1
CELL, MOLECULAR AND SYSTEMS BIOLOGY: METABOLOMICS, TRANSCRIPTOMICS, LIPIDOMICS, PROTEOMICS
Hall F2
17:30-18:30
FORUM 04: TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES? SMALL MOLECULES FOR SYMPTOMATIC & DISEASE MODIFICATION?
Hall A
18:30-18:40
SHORT BREAK
Exhibition
18:40-20:15
INDUSTRY SYMPOSIUM 08 (NO CME/CPD CREDIT)
Hall A
Friday April 04, 2025
07:00-08:00
ON-DEMAND SYMPOSIA - ONLINE ONLY
On-Demand Oral Gallery
08:00-08:30
PLENARY LECTURE 05
Hall A
08:30-08:40
BREAK
Exhibition
08:40-10:40
INDUSTRY SYMPOSIUM 09 (NO CME/CPD CREDIT)
Hall A
CEREBROVASCULAR CHANGES, CAA, BBB 01
Hall E
PREVENTION AND THERAPEUTIC INTERVENTIONS IN AD
Hall B
PATHOLOGY OF NEURODEGENERATIVE DISEASES: UPDATES AND NEW FINDINGS
Hall C
BRAIN GUT INTERACTIONS, MICROBIOME
Hall F1
FLUID BIOMARKERS AND IMAGING 02
Hall F2
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
11:10-12:50
INDUSTRY SYMPOSIUM 10 (NO CME/CPD CREDIT)
Hall A
12:50-13:50
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
Exhibition
13:50-15:50
INDUSTRY SYMPOSIUM 11 (NO CME/CPD CREDIT)
Hall A
FLUID AND DIGITAL BIOMARKERS AND IMAGING
Hall E
IMMUNITY AND INFLAMMATION IN NEURODEGENERATION
Hall B
LRKK2, ALPHA-SYNUCLEIN, PARKIN: DIAGNOSIS AND THERAPEUTIC TARGETS
Hall C
TAU AGGREGATION, PROPAGATION, DEPOSITION, AND PROTEIN MODIFICATIONS
Hall F1
RESILIENCE, LONGEVITY AND DRIVERS OF DISEASE PROGRESSION
Hall F2
15:50-16:20
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
16:20-17:20
INDUSTRY SYMPOSIUM 12 (NO CME/CPD CREDIT)
Hall A
16:20-18:20
MRI
Hall E
FLUID BIOMARKERS AND IMAGING 03
Hall B
DISEASE MECHANISMS, SYNAPSE PATHOLOGY & FUNCTION; INFLAMMATION: THERAPEUTIC TARGETS
Hall C
MICROGLIA
Hall F1
AD & PD: INSIGHTS FROM GENETICS 02
Hall F2
17:25-18:30
FORUM 05: NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA
Hall A
18:30-18:40
SHORT BREAK
Exhibition
18:40-20:00
INDUSTRY SYMPOSIUM 13 (NO CME/CPD CREDIT)
Hall A
18:40-19:40
PATHOPHYSIOLOGY, NEUROGENESIS. GLYMPHATIC/LYMPHATIC INFLAMMATION
Hall B
CELL REPLACEMENT THERAPY & DIAGNOSTICS: CELLS, GLIA AND GRAFTS
Hall C
TAU PATHOLOGIES, PSP, LBD
Hall F1
COGNITIVE TRAJECTORIES, DIGITAL TWINS, POSTERIOR CORTICAL ATROPHY
Hall F2
Saturday April 05, 2025
07:00-08:00
ON-DEMAND SYMPOSIA - ONLINE ONLY
On-Demand Oral Gallery
08:00-08:30
PLENARY LECTURE 06
Hall A
08:30-08:40
BREAK
Exhibition
08:40-10:40
ABETA TARGETING THERAPIES IN AD 02
Hall A
BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS
Hall E
TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS
Hall B
CEREBROVASCULAR CHANGES, CAA, BBB 02
Hall C
FLUID BIOMARKERS AND IMAGING IN AD, PD , LBD. PSP AND SMALL- VESSEL DISEASE
Hall F1
MECHANISMS (TDP-43, C9ORF72, TMEM106B) AND CLINICAL TRIALS IN FTD, ALS AND NEURODEGENERATION 02
Hall F2
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
11:10-13:10
TAUOPATHIES: CHALLENGES IN TARGETING TAU
Hall A
ABETA & TAU IMMUNOTHERAPIES
Hall E
NOVEL THERAPEUTIC STRATEGY BEYOND AMYLOID AND TAU: NEUROTRANSMITTERS AND RECEPTORS: GLP-1 ANALOGUES
Hall B
CHOLINERGIC MECHANISMS IN AD AND PD (2)
Hall C
AD & PD: TOWARDS NOVEL THERAPEUTIC INTERVENTION
Hall F1
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 01
Hall F2
13:10-14:10
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
Exhibition
14:10-15:10
FORUM 06: CHALLENGES AND OPPORTUNITIES FOR ANTI-TAU THERAPIES IN CLINICAL TRIALS – HOW CAN WE MAKE HOPES COME TRUE?
Hall A
14:10-16:10
PD AND LBD: ADVANCES IN DIAGNOSIS AND DRUG DEVELOPMENT
Hall E
SECRETASES AND APP PROCESSING
Hall B
ALPHA-SYNUCLEINOPATHIES: MECHANISMS, PATHOPHYSIOLOGY AND MODELLING OF PROGRESSION 02
Hall C
EEG, DIAGNOSTCS AND OTHER ASSESSMENT TOOLS
Hall F1
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 02
Hall F2
15:10-16:10
FORUM 07: THERAPY FOR AD, PD & LBD: NOVEL TRANSLATIONAL MODELS, NEW RECEPTOR- AND NEUROINFLAMMATION-BASED TARGETS – HOW CLOSE ARE WE TO SUCCESS?
Hall A
16:10-16:40
EXHIBITION, POSTERS AND COFFEE BREAK
Exhibition
16:40-17:40
FORUM 08: DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TO APPROVAL – HOW TO DEFINE SUCCESS?
Hall A
16:40-18:40
ADVANCES IN AD DRUG DEVELOPMENT 02
Hall E
ADVANCES IN PD, LBD AND MSA DRUG DEVELOPMENT
Hall B
TRANSLATIONAL DRUG DEVELOPMENT AND EXPERIMENTAL MODELS
Hall C
COVID-19 AND IMPACTS ON NEURODEGENERATION
Hall F1
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD 03
Hall F2
17:45-19:00
ADVANCES IN AD DRUG DEVELOPMENT 03
Hall A
19:00-19:20
CLOSING CEREMONY
Hall A